Memantine is a specific, noncompetitive NMDA-receptor antagonist which has a novel mechanism of action for the treatment of patients with moderately severe to severe Alzheimer’s Disease and vascular dementia. It is the first and only drug approved worldwide for the treatment of the advanced stages of Alzheimer's disease. In clinical tests, Memantine was found to provide rapid and enduring improvement in the cognitive, psychological, social and motor impairments of dementia. These symptomatic improvements lead to an increased quality of life of the patients and reduced home care efforts. Memantine is sold under the brand names of Axura ® , Ebixa ® and Namenda ® .
Links to more information regarding Memantine Axura ® Ebixa ® Namenda ®
-
Memantine (Namenda ® ), prescribing information
Memantine questions and answers
Memantine summary and test results
Memantine research links and news
Memantine fact sheet by the Alzheimer's Association
Memantine more information from the Alzheimer's Association
Memantine Officially approved for use in U.S.
Memantine Efficacy and safety of memantine in patients with mild to moderate vascular dementia
Memantine.com Product information, tests and studies
Memantine Order Memantine Axura ®
Dosage:The recommended dosage for Memantine is 20mg per day. To lower the risk of side effects the daily dosage should gradually be increased from 5mg to 20mg over four weeks.
Precautions: Memantine use should be carefully monitored by your doctor if you have a history of seizures or have recently had a heart attack, kidney disease or untreated hypertension.
Memantine may interact with some other drugs such as Dextromethorphane, Cimetidine, procainamide, hydrochlorothiazide, anticholinergics, anticonvulsives, barbituates or dopaminergic antagonists like L-dopa or bromocriptine. Make sure the doctor knows what else the person with dementia is taking.